06.24.20
PLT Health Solutions, in partnership with Laila Nutraceuticals, announced that it is launching a new active and sports nutrition ingredient formulated with a low dose of Boswellia serrata formulated for joint comfort and muscle recovery.
The new product, Dynaleve Muscle + Joint Formula, was evaluated in a 2019 clinical study using a delayed onset muscle soreness (DOMS) model, and was shown to not only relieve joint discomfort previously demonstrated by PLT’s prior Boswellia serrata ingredients, but that it was also able to aid in the recovery of muscle soreness and strength post-exercise. Endpoints within the DOMS assessment included more than just soreness- it also included strength recovery, knee soreness, overall stiffness, and “perceived exertion” in physical activity subsequent to exercise. The study also demonstrated improvements in biomarkers related to inflammation, muscle damage, and connective tissue damage.
While joint health within the dietary supplements world has traditionally skewed toward areas such as healthy aging and products which could potentially relieve joint damage concurrent with certain health conditions, this product and its associated research represent a focus on joint health among athletic consumers, a trend which PLT Health Solutions’ president and CEO, Seth Flowerman, said has the potential to flourish within this market category.
“Dynaleve is such a novel and powerful ingredient in that it supports both muscle and joint comfort,” Flowerman said. “The new study points to an ingredient that can change the landscape of the active and sports nutrition market by offering a comprehensive, low dose solution to post-exercise recovery, while promoting the ability to perform at a higher level with less recovery time. At the same time, this study highlights the potential for Dynaleve to help people feel better faster in their day to day lives – things like climbing stairs or walking with less stiffness can be made easier.”
In the 2019 study, 50 recreationally active men between the ages of 25 and 40 were studied for their response to eccentric exercise-related delayed-onset muscle soreness, and were grouped using randomization, double-blindness, and a placebo group. Those who received supplementation took 60 mg of Dynaleve daily for 10 days, with an eccentric exercise intervention on day seven. Testing occurred at baseline and on days 7-10.
The assessment demonstrated that the Dynaleve group saw a 47% reduction in muscle soreness during squats (muscle recovery) and a 31% reduction in knee soreness, versus the participants who took a placebo. 96% of participants on Dynaleve were observed to have fully recovered their strength after three days, compared to about 38% of the placebo group. The perceived exertion of exercise was reported 27% lower by the Dynaleve subjects. Significant improvements in flexibility were also observed, the authors of the study said. Additionally, the Dynaleve group exhibited reduced levels of inflammatory biomarkers.
This trial represents the second human clinical study on Dynaleve, in addition to the three pre-clinical studies of the ingredient.
Flowerman said that Dynaleve’s neutral flavor profile and water solubility make it an ideal ingredient for sports nutrition formulation, beyond conventional pill and capsule formats.
“Dynaleve was specifically developed as a low-dose, neutral-tasting, and soluble solution for ease of incorporation into a broad range of applications and delivery systems,” Flowerman said. “This solution represent a significant invention in its own right as it overcomes the traditional challenges of incorporating Boswellia serrata into organoleptically sensitive and water-soluble formulations. Beyond innovative product forms, we see the potential for dramatic consumer messaging with Dynaleve. We think athletes and regular gym visitors will like the idea of a quicker and easier return to workouts, or to be able to exercise harder, sooner. We also feel that the ability to enjoy an active lifestyle – every day – will be attractive to seniors or people who are looking to stay in shape or lose weight. We’re excited about how innovative consumer products companies will put this new ingredient and new science to work.”
The new product, Dynaleve Muscle + Joint Formula, was evaluated in a 2019 clinical study using a delayed onset muscle soreness (DOMS) model, and was shown to not only relieve joint discomfort previously demonstrated by PLT’s prior Boswellia serrata ingredients, but that it was also able to aid in the recovery of muscle soreness and strength post-exercise. Endpoints within the DOMS assessment included more than just soreness- it also included strength recovery, knee soreness, overall stiffness, and “perceived exertion” in physical activity subsequent to exercise. The study also demonstrated improvements in biomarkers related to inflammation, muscle damage, and connective tissue damage.
While joint health within the dietary supplements world has traditionally skewed toward areas such as healthy aging and products which could potentially relieve joint damage concurrent with certain health conditions, this product and its associated research represent a focus on joint health among athletic consumers, a trend which PLT Health Solutions’ president and CEO, Seth Flowerman, said has the potential to flourish within this market category.
“Dynaleve is such a novel and powerful ingredient in that it supports both muscle and joint comfort,” Flowerman said. “The new study points to an ingredient that can change the landscape of the active and sports nutrition market by offering a comprehensive, low dose solution to post-exercise recovery, while promoting the ability to perform at a higher level with less recovery time. At the same time, this study highlights the potential for Dynaleve to help people feel better faster in their day to day lives – things like climbing stairs or walking with less stiffness can be made easier.”
In the 2019 study, 50 recreationally active men between the ages of 25 and 40 were studied for their response to eccentric exercise-related delayed-onset muscle soreness, and were grouped using randomization, double-blindness, and a placebo group. Those who received supplementation took 60 mg of Dynaleve daily for 10 days, with an eccentric exercise intervention on day seven. Testing occurred at baseline and on days 7-10.
The assessment demonstrated that the Dynaleve group saw a 47% reduction in muscle soreness during squats (muscle recovery) and a 31% reduction in knee soreness, versus the participants who took a placebo. 96% of participants on Dynaleve were observed to have fully recovered their strength after three days, compared to about 38% of the placebo group. The perceived exertion of exercise was reported 27% lower by the Dynaleve subjects. Significant improvements in flexibility were also observed, the authors of the study said. Additionally, the Dynaleve group exhibited reduced levels of inflammatory biomarkers.
This trial represents the second human clinical study on Dynaleve, in addition to the three pre-clinical studies of the ingredient.
Flowerman said that Dynaleve’s neutral flavor profile and water solubility make it an ideal ingredient for sports nutrition formulation, beyond conventional pill and capsule formats.
“Dynaleve was specifically developed as a low-dose, neutral-tasting, and soluble solution for ease of incorporation into a broad range of applications and delivery systems,” Flowerman said. “This solution represent a significant invention in its own right as it overcomes the traditional challenges of incorporating Boswellia serrata into organoleptically sensitive and water-soluble formulations. Beyond innovative product forms, we see the potential for dramatic consumer messaging with Dynaleve. We think athletes and regular gym visitors will like the idea of a quicker and easier return to workouts, or to be able to exercise harder, sooner. We also feel that the ability to enjoy an active lifestyle – every day – will be attractive to seniors or people who are looking to stay in shape or lose weight. We’re excited about how innovative consumer products companies will put this new ingredient and new science to work.”